CY1107913T1 - Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc - Google Patents

Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc

Info

Publication number
CY1107913T1
CY1107913T1 CY20081100369T CY081100369T CY1107913T1 CY 1107913 T1 CY1107913 T1 CY 1107913T1 CY 20081100369 T CY20081100369 T CY 20081100369T CY 081100369 T CY081100369 T CY 081100369T CY 1107913 T1 CY1107913 T1 CY 1107913T1
Authority
CY
Cyprus
Prior art keywords
ftc
cis
forms
manufacture
polymorphic
Prior art date
Application number
CY20081100369T
Other languages
English (en)
Inventor
Kenneth R Phares
Devalina Law
Yuerong Hu
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1107913T1 publication Critical patent/CY1107913T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Στερεές φάσεις του (-)-cis-FTC, οι οποίες ορίζονται εδώ ως άμορφο (-)-PTC και Μορφές II και III (-)-cis-FTC) παρέχονται, οι οποίες μπορεί να διακρίνονται από τη Μορφή I (-)-cis-FTC με πρότυπα διάθλασης σκόνης ακτίνων-Χ, θερμικές ιδιότητες και μεθόδους βιομηχανικής κατασκευής. Μια ένυδρη κρυσταλλική μορφή (±)-cis-FTC (δηλ. ρακεμικό cis-FTC) και αφυδατωμένη μορφή του υδρίτη, επίσης παρέχονται και μπορεί παρομοίως να διακρίνονται από άλλες μορφές FTC με πρότυπα διάθλασης σκόνης ακτίνων-Χ, θερμικές ιδιότητες και μεθόδους βιομηχανικής κατασκευής. Αυτές οι FTC μορφές μπορεί να χρησιμοποιηθούν στη βιομηχανική κατασκευή άλλων μορφών FTC ή σε φαρμακευτικές συνθέσεις. Ιδιαιτέρως προτιμώμενες χρήσεις αυτών των μορφών είναι στη θεραπεία HIV ή ηπατίτιδας Β.
CY20081100369T 2001-03-01 2008-03-31 Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc CY1107913T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27256001P 2001-03-01 2001-03-01
US30960501P 2001-08-02 2001-08-02
EP05076347A EP1574512B1 (en) 2001-03-01 2002-03-01 Polymorphic and other crystalline forms of cis-FTC

Publications (1)

Publication Number Publication Date
CY1107913T1 true CY1107913T1 (el) 2013-09-04

Family

ID=26955597

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061100192T CY1107983T1 (el) 2001-03-01 2006-02-10 Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
CY20081100369T CY1107913T1 (el) 2001-03-01 2008-03-31 Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20061100192T CY1107983T1 (el) 2001-03-01 2006-02-10 Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc

Country Status (14)

Country Link
US (3) US6723728B2 (el)
EP (3) EP1574512B1 (el)
JP (4) JP5105689B2 (el)
KR (4) KR101015510B1 (el)
CN (4) CN1503796B (el)
AT (2) ATE312097T1 (el)
AU (1) AU2002335489B2 (el)
CA (4) CA2690137C (el)
CY (2) CY1107983T1 (el)
DE (2) DE60224592T2 (el)
DK (2) DK1389207T3 (el)
ES (3) ES2299950T3 (el)
PT (2) PT1574512E (el)
WO (1) WO2002070518A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690137C (en) 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
EP2350065A1 (en) 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
EP0141927B1 (en) 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
JPH07500573A (ja) 1991-07-12 1995-01-19 ネクススター・ファーマシューティカルズ・インコーポレイテッド 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
SE9500872L (sv) * 1995-03-10 1996-04-01 Tony Wiseby Anordning vid sikte för pilbåge
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE19543707A1 (de) * 1995-11-23 1997-05-28 Inst Neue Mat Gemein Gmbh Verfahren zum Konservieren von Papier
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
US6071922A (en) 1997-03-19 2000-06-06 Emory University Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
RU2439069C2 (ru) * 1998-08-12 2012-01-10 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиолановых нуклеозидов
PT1119635E (pt) 1998-10-09 2012-07-24 Gilead Sciences Inc Sistemas não homogéneos para a resolução de misturas enantioméricas
CA2690137C (en) * 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
US6723728B2 (en) 2004-04-20
US20090306114A1 (en) 2009-12-10
EP1903041A3 (en) 2008-04-23
JP2015028045A (ja) 2015-02-12
KR20040002871A (ko) 2004-01-07
CN102911165A (zh) 2013-02-06
CN1503796A (zh) 2004-06-09
ES2299950T3 (es) 2008-06-01
EP1574512B1 (en) 2008-01-09
CN102942563A (zh) 2013-02-27
DE60207850T2 (de) 2006-08-10
US20030060645A1 (en) 2003-03-27
KR20080065316A (ko) 2008-07-11
EP1574512A1 (en) 2005-09-14
PT1903041E (pt) 2015-06-23
KR101150250B1 (ko) 2012-06-12
CN102911165B (zh) 2016-08-17
CA2867970A1 (en) 2002-09-12
JP2004530660A (ja) 2004-10-07
ES2537007T3 (es) 2015-06-01
CN102911166B (zh) 2016-08-17
US7544692B2 (en) 2009-06-09
CN102911166A (zh) 2013-02-06
KR20100091265A (ko) 2010-08-18
AU2002335489B2 (en) 2008-06-05
CA2439831C (en) 2010-01-12
JP2013040192A (ja) 2013-02-28
EP1389207A1 (en) 2004-02-18
US8637535B2 (en) 2014-01-28
KR100927024B1 (ko) 2009-11-17
CA2690137C (en) 2012-11-13
KR101015510B1 (ko) 2011-02-16
CA2788498A1 (en) 2002-09-12
KR20080065317A (ko) 2008-07-11
WO2002070518A1 (en) 2002-09-12
CA2690137A1 (en) 2002-09-12
JP5105689B2 (ja) 2012-12-26
EP1389207B1 (en) 2005-12-07
DE60224592D1 (de) 2008-02-21
ATE312097T1 (de) 2005-12-15
CA2439831A1 (en) 2002-09-12
DK1389207T3 (da) 2006-04-18
DE60224592T2 (de) 2009-01-29
EP1903041A2 (en) 2008-03-26
US20050026934A1 (en) 2005-02-03
JP2009197005A (ja) 2009-09-03
EP1903041B1 (en) 2015-02-18
CY1107983T1 (el) 2013-09-04
DK1574512T3 (da) 2008-03-03
PT1574512E (pt) 2008-03-05
DE60207850D1 (de) 2006-01-12
CN1503796B (zh) 2012-07-04
ES2253544T3 (es) 2006-06-01
CA2788498C (en) 2016-02-16
ATE383355T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
CY1106969T1 (el) Αναστολεις dpp-iv
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
SE0102315D0 (sv) Compounds
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
DE60329237D1 (de) Kristalline form von linezolid
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
CY1110240T1 (el) Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου
EP1764092A3 (en) Selecting compounds for treatment of Alzheimer's disease
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
DE60020967D1 (de) Kristalle von lansoprazole
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
WO2005004805A3 (en) Thermally stable crystalline epirubicin hydrochloride and method of making the same
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
MXPA04006041A (es) Antivirales de piridoquinoxalina.
DK1270575T3 (da) Hidtil ukendt krystallinsk form af et pyrrolidylthiocarbapenemderivat
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
DK1353906T3 (da) Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf